Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies

NCT03682289 is registered in ClinicalTrials.gov with Rahul Aggarwal as lead sponsor.

NCT NCT03682289
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03682289 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies
Lead sponsor
Rahul Aggarwal
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 17, 2019
Completion date
March 31, 2028
Enrollment
83 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, endometrial cancer, locally advanced malignant solid neoplasm, locally advanced pancreatic cancer, metastatic castration-resistant prostate cancer, metastatic malignant solid neoplasm, metastatic pancreatic cancer, metastatic renal cell carcinoma, metastatic urothelial carcinoma, stage iii pancreatic cancer, stage iii renal cell cancer, stage iv pancreatic cancer, stage iv renal cell cancer